Name | Sodium risedronate |
---|---|
Synonyms |
T6NJ C1XQPQQO&PQQO &&Mono Na salt
Actonel Natriumhydrogen-(1-hydroxy-1-phosphono-2-pyridin-3-ylethyl)phosphonat Risedronic acid monosodium salt sodium hydrogen (1-hydroxy-1-phosphono-2-pyridin-3-ylethyl)phosphonate Benet hydrogène (1-hydroxy-1-phosphono-2-pyridin-3-yléthyl)phosphonate de sodium Phosphonic acid, [1-hydroxy-2-(3-pyridinyl)ethylidene]bis-, sodium salt (1:1) MFCD01706268 phosphonic acid, [1-hydroxy-2-(3-pyridinyl)ethylidene]bis-, monosodium salt Sodium risedronate sodium hydrogen [1-hydroxy-1-phosphono-2-(pyridin-3-yl)ethyl]phosphonate P,P'-[1-Hydroxy-2-(3-pyridonyl)ethylidene]bis-phosphonic acid sodium salt Sodium hydrogen [1-hydroxy-1-phosphono-2-(3-pyridinyl)ethyl]phosphonate Risedronic acid sodium salt sodium hydrogen-1-hydroxy-1-phosphono-2-(pyridin-3-yl)ethylphosphonate [1-Hydroxy-2-(3-pyridinyl)ethylidene]bis(phosphonic acid), sodium salt (1:1) Optinate Risedronate sodium |
Description | Risedronate sodium is a pyridinyl biphosphonate which inhibits osteoclast-mediated bone resorption.Target: Risedronate sodium, which was promoted in Croatia a few months ago, is the latest (III) generation of bisphosphonates, the most efficient anti-resorption drugs that inhibit osteoclast-mediated bone resorption and change the bone metabolism. Risedronate sodium is hence the first line of bisphosphonates for the reduction of vertebral and non-vertebral fracture risks in postmenopausal women with osteoporosis or those with a high risk of osteoporosis. It also efficiently prevents bone loss or improves bone density in men and women on a long-term corticosteroid therapy [1].The administration of 20 and 25 mg/kg risedronate sodium for 4 days led to decreases of parasitemia of 68.9% and 83.6%, respectively. On the seventh day of treatment the inhibitions were 63% and 88.9% with 20 and 25 mg/kg, respectively. After recovering the parasitemia, a dose-response curve was obtained for estimating the ID50 (dose causing 50% inhibition), equivalent to 17 ± 1.8 mg/kg after 7 days of treatment. Four days after the interruption of treatment (11 days postinfection), the parasitemias of the groups treated with 10, 15, 20, and 25 mg/kg/day were 15.3%, 15.9%, 15.2%, and 5.7%, respectively. Conversely, the group that received PBS presented parasitemia of 25.6%. Among the groups treated with risedronate sodium, only the animals that received 25 mg/kg had a significant inhibition of 77.8% (see Table S1 in the supplemental material), demonstrating that even after treatment discontinuation, the parasitemia of the animals remained low in relation to that of the controls [2].Clinical indications: Bone resorption; Male osteoporosis; Osteogenesis imperfecta; Osteoporosis; Pagets bone disease Toxicity: abdominal pain; anxiety, back pain; belching, bladder irritation; bone disorders and pain; bronchitis; bursitis; cataracts; chest pain; colitis; constipation; depression; diarrhea; difficulty breathing |
---|---|
Related Catalog | |
References |
Boiling Point | 692.3ºC at 760 mmHg |
---|---|
Melting Point | 252-262°C |
Molecular Formula | C7H10NNaO7P2 |
Molecular Weight | 305.094 |
Flash Point | 372.5ºC |
Exact Mass | 304.983032 |
PSA | 170.63000 |
LogP | 0.06380 |
Vapour Pressure | 4.03E-20mmHg at 25°C |
Storage condition | Store at RT |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
Symbol |
GHS07 |
---|---|
Signal Word | Warning |
Hazard Statements | H302 + H312 + H332 |
Precautionary Statements | P280 |
Hazard Codes | Xi |
RIDADR | NONH for all modes of transport |
RTECS | SZ8567500 |